NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...
The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...
At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback